David M. Santangelo

David M. Santangelo

Of Counsel

New York, NY
Phone: 212.808.2708    Fax: 212.286.9806

santangelod@pepperlaw.com

Transactions in the life sciences / pharmaceuticals sector in which Mr. Santangelo has participated include representing:

  • Sunovion Pharmaceuticals Inc. in connection with its disposition of a portfolio of U.S. based assets and rights for the treatment of respiratory diseases and conditions to Covis Pharma B.V.
  • Windtree Therapeutics, Inc. in connection with its entry into an Exclusive License and Collaboration Agreement for the development and commercialization of its KL4 Surfactant Technology Platform in Asia with Lee’s Pharmaceutical (HK) Limited
  • Aevi Genomic Medicine Inc. (f/k/a Medgenics Inc.) in connection with its entry into a clinical development and option agreement with Kyowa Hakko Kirin Co., Ltd. (for the development and potential commercialization of a first-in-class anti-LIGHT monoclonal antibody for the treatment of severe pediatric onset IBD and other indications)
  • Fibrocell Science, Inc. in connection with its entry into an exclusive channel collaboration agreement with Intrexon Corporation (for the development and commercialization of genetically-modified fibroblasts to treat chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions)
  • an international pharmaceutical company in connection with its negotiation of a research collaboration and exclusive option agreement with a privately owned biotherapeutics company (to identify and validate targets and develop antibodies and antibody drug conjugates for the treatment of haematological malignancy indications)
  • an international pharmaceutical company in connection with its negotiation of a collaboration and license agreement with a publicly traded biopharmaceutical company (for a small molecule receptor tyrosine kinase inhibitor for the treatment of acute myeloid leukemia)
  • a pharmaceutical company in connection with its entry into a license, development and commercialization agreement with subsidiaries of a publicly traded global medical technology company (regarding pairing a late stage injectable pain therapy with a novel medical device delivery system)
  • an international pharmaceutical company in connection with its entry into option and asset purchase agreements with a privately owned company specializing in light infusion therapies (for talaporfin sodium and a drug-device combination product for the treatment of benign prostatic hyperplasia, solid tumors and other indications)
  • an international pharmaceutical company in connection with its negotiation of a license, development and commercialization agreement with a privately owned clinical stage drug discovery and development company (for a formulation of IFN-Beta to be administered intravenously for the treatment of acute respiratory distress syndrome)
  • an international pharmaceutical company in connection with its negotiation of a license agreement with the subsidiary of a global biopharmaceutical company (for a pressurized metered dose inhaler and an inhalable proprietary formulation of glycopyrronium bromide and/or formoterol fumarate)
  • an India-based pharmaceutical company in connection with its entry into a license and supply agreement with a subsidiary of a publicly traded science and technology-based company (for the manufacture and sale of soy nutrition products)
  • Mundipharma International Corporation Limited and Mundipharma Medical Company in connection with their entry into strategic collaboration and supply agreements with Allos Therapeutics, Inc. (to co-develop FOLOTYN® (pralatrexate injection), a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma, outside the U.S. and Canada)
  • Mundipharma International Corporation Limited and Purdue Pharma L.P. in connection with their entry into strategic alliance agreements with Infinity Pharmaceuticals, Inc. (in the areas of oncology and analgesics)
  • Purdue Pharma L.P. in connection with its asset acquisition of Dilaudid® from a global, publicly traded research-based biopharmaceutical company
  • Purdue Pharma L.P. and its network of independent associated companies in connection with the settlement of patent litigation related to OxyContin®
  • NPS Pharmaceuticals, Inc. in connection with its tender offer to purchase for cash all of its outstanding 3 percent convertible notes due in 2008
  • an international pharmaceutical company in connection with a licensing transaction in Japan in which it granted an exclusive license for the sale and distribution rights of a product in development for the treatment of nonmalignant chronic moderate to severe pain to a Japan-based pharmaceutical company
  • Purdue Pharma L.P. in connection with its entry into an exclusive license, commercialization and supply agreement with Labopharm Europe Limited (for the development and marketing of a once daily tramadol product in the U.S.)
  • Purdue Pharma L.P. in connection with its entry into authorized generic agreements with Watson Pharmaceuticals, Inc. (for the distribution and sale of OxyContin® and MS Contin® in the U.S.).

Transactions in other industry sectors in which Mr. Santangelo has participated include representing:

  • The Southern Cross Group in connection with proposed venture capital investments in a Latin American homebuilder and Canadian oil / natural gas company
  • Rockwell Collins, Inc. in its acquisition of all of the outstanding stock of Anzus, Inc., a software manufacturer
  • Arcor S.A.I.C (Grupo Arcor), an Argentine confectionery company, in connection with its offering of $200 million aggregate principal amount of non-convertible notes issued pursuant to the company’s short and medium term note program
  • ArvinMeritor, Inc. in connection with its $200 million Rule 144A private offering of its 4 percent convertible senior notes due 2027
  • Arroyo Energy Investors LP, a subsidiary of The Bear Sterns Companies Inc. (now JPMorgan Chase & Co.), in connection with the purchase by Arroyo of a portfolio of energy projects and power assets from Delta Power Holdings, LLC
  • Fortune Brands, Inc., in the spin-off of its ACCO World Corporation office products unit and the subsequent merger of ACCO with General Binding Corporation
  • El Paso Corporation in connection with its sale of a portfolio of energy projects and power assets in excess of $700 million to a subsidiary of American International Group
  • El Paso Corporation in connection with the sale of a major power project located in Linden, New Jersey, to the Goldman Sachs Group, Inc.
  • El Paso Corporation in connection with the sale of cogeneration facilities located in Camden, Bayonne and Newark, New Jersey
  • Conexant Systems, Inc. in connection with the merger of its wireless communications business with Alpha Industries, Inc., following the spin-off of Conexant’s wireless communications business to Conexant shareholders.

Education

  • J.D., Northwestern University School of Law, 2001
  • B.A., Economics and Government, with distinction, Cornell University, 1998

Bar Admissions

  • New York

Practice Areas

Data protection laws have changed, so we have revised our Privacy Policy.

CLOSE